Chemical structure of molecule linrodostat inhibitor

oral sel. IDO1 dioxygenase inhibitor

100 mg QD, in I/O combo studies for cancer

acts on apo-IDO1 displacing heme co-factor

Mol. Cancer Ther., Dec. 9, 2020

BMS, Princeton, NJ / Flexus, San Carlos, CA

Bristol Myers Squibb (BMS) oral selective heme-displacing IDO1 inhibitor

 this content is exclusive to
Premium members

Upgrade to a Premium Drug Hunter membership to unlock the full content and start reading now.